Ticlopidine hydrochloride

White Solid

Ticlid,Millot,France,1978

mucolytic, antibacterial, surface active agent

An antithrombotic. a platelet aggregation inhibitor

Ticlopidine hydrochloride is a selective P2Y12 receptor antagonist. It inhibits ADP-induced platelet aggregation and displays antithrombotic activity following oral administration in vivo.

A solution of thieno[3,2-c]pyridine (13.5 g; 0.1 mol) and 2-chlorobenzyl chloride (17.7 g) in acetonitrile (150 ml) is boiled during 4 hours. After evaporation of the solvent, the solid residue consists of 5-(2- chlorobenzyl)-thieno[3,2-c]pyridinium chloride which melts at 166°C (derivative n° 30). This compound is taken up into a solution comprising ethanol (300 ml) and water (100 ml). Sodium borohydride (NaBH4)(20 g) is added portionwise to the solution maintained at room temperature. The reaction medium is maintained under constant stirring during 12 hours and is then evaporated. The residue is taken up into water and made acidic with concentrated hydrochloric acid to destroy the excess reducing agent. The mixture is then made alkaline with ammonia and extracted with ether. The ether solution is washed with water, dried and evaporated. The oily residue is dissolved in isopropanol (50 ml) and hydrochloric acid in ethanol solution is then added thereto.
After filtration and recrystallization from ethanol, there are obtained 5-(2- chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride crystals (yield: 60%) having a melting point (Koefler block) of 190°C.

Platelet aggregation inhibitor

Selective P2Y 12 receptor antagonist. Inhibits ADP-induced platelet aggregation and displays antithrombotic activity following oral administration in vivo .

[1] Chemical and Pharmaceutical Bulletin, 1994, vol. 42, # 8, p. 1676 - 1678
[2] Patent: CN105461735, 2016, A. Location in patent: Paragraph 0020; 0021
[3] Patent: CN105541862, 2016, A. Location in patent: Paragraph 0015; 0019